Eris Lifesciences Acquires Novartis’ Zomelis (vildagliptin) in India for $13M

Shots:

• Eris Lifesciences acquired Novartis’ novel therapy Zomelis for $13M (~INR 93 crore) and will initiate the commercialization of product from Dec 10, 2019 in India
• The acquisition of Zomelis will robust Eris Lifesciences’ presence with the enhancement of its diabetic portfolio in India and allow Eris to strengthen its products offering for patients with diabetes
•  Zomelis is a therapy to treat type 2 diabetes and is the first innovator pharmaceutical product trademark acquisition by Eris. Additionally, Eris acquired Strides Shasun’ branded business portfolio to strengthen its footprints in the CNS segment for INR500 crore

Click here to­ read full press release/ article | Ref: Business Standards | Image: 1mg